Welcome : Guest

Biobetters Trends

Abstract

The report analyzes and presents an overview of Biobetters market worldwide. "Biobetters or Biosuperiors are novel molecules derived from successful, approved biologic products that have been customized to enhance its overall efficacy. The primary characteristics targeted by these applicants include extended half-life in human body, improved bioavailability, lower immunogenicity, higher purity, and fewer side-effects. These molecules contain the same active ingredients such as antibodies to target the same protein, but feature different chemical or molecular properties than the original drug."

The report further discusses about applications, future prospects, and comparison of biobetters with originator drugs and biosimilars along with the strategic industry activities of major companies worldwide. In addition, major companies operating in the Biobetters arena worldwide including Amgen Inc., Cantab Biopharmaceuticals Ltd., Crucell NV, GreenCross Corporation, Hanmi Pharm Co. Ltd., Medgenics Inc., PharmaEssentia Corporation, Polytherics Ltd., SynBio LLC, Teva Pharmaceutical Industries Ltd., Xencor Inc., and others are profiled.

Code: 146053
Price: $950
Companies : 30
Pages: 14
Date: January, 2014
Market Data Tables : -

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
A Prelude......1
Biobetters - A Better Bet......1
Originator Drugs vs. Biobetters......2
Biosimilars vs. Biobetters......2
An Evolution from Biotherapeutics to Biologics......3
Biobetter - The Gold Rush......3
Biotechnology Start-ups Focus on Biobetter Route......4
US Regulatory Scenario......4
Synthon Takes Over Key Platforms of Biolex Therapeutics......5
Xencor Signs Agreement with Boehringer Ingelheim......5
Catalent Pharma Solutions Inks Agreement with Aptuit......5
Compass Biotechnologies Establishes New Subsidiaries......6
Human Stem Cells Institute Announces SynBio Project......6
Lancaster Laboratories Enters into Partnership with BioAzure Technologies......6
Momenta Pharmaceuticals Inks Agreement with Virdante Pharmaceuticals......7
PolyTherics Inks Agreement with DSM BioSolutions......7
Watson Pharmaceuticals Acquires Eden Biopharm Group......7
Amgen, Inc. (USA)......8
Bolder BioTechnology, Inc. (USA)......8
Boryung Pharmaceutical Co., Ltd. (Korea)......8
Caliber Biotherapeutics LLC (USA)......8
Cantab Biopharmaceuticals Ltd. (UK)......8
Celtrion, Inc. (Korea)......9
ChromaCon AG (Switzerland)......9
Crucell NV (The Netherlands)......9
F. Hoffmann-La Roche Ltd. (Switzerland)......9
Flamel Technologies SA (France)......9
Genentech, Inc. (USA)......10
Glycotope GmbH (Germany)......10
GreenCross Corporation (Korea)......10
HanAll BioPharma Co., Ltd. (Korea)......11
Hanmi Pharm Co., Ltd. (Korea)......11
Harvest Moon Pharmaceuticals USA, Inc. (USA)......11
Medgenics, Inc. (USA)......11
OPKO Health Inc. (USA)......11
Pfizer, Inc. (USA)......12
PharmaEssentia Corporation (Taiwan)......12
Pieris AG (Germany)......12
Polytherics Ltd. (UK)......12
rEVO Biologics (USA)......13
Sutro Biopharma, Inc. (USA)......13
SynBio LLC (Russia)......13
Synthon (The Netherlands)......13
Teva Pharmaceutical Industries Ltd. (Israel)......13
Theramyt Novobiologics Pvt., Ltd. (India)......14
Vitapharm Technology Development Co., Ltd. (China)......14
Xencor, Inc. (USA)......14